FILTER
BY CATEGORY

View All

COVID-19 Stay Tuned Nutrition For implementers For policymakers Report For researchers Research Urban Health M&E
HIV/AIDS

Guidelines on long-acting injectable cabotegravir for HIV prevention

08 Aug 2022

Overview

In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at reducing the risk of HIV acquisition.

This guideline provides implementation considerations to support Member States, program managers, policymakers, researchers, health workers, communities, and other stakeholders in the implementation of projects and programs for CAB-LA. It also outlines critical research gaps for CAB-LA.

To read the guideline, please click the linked file. 

Download PDF
PUBLISHED BY
WHO
YEAR OF PUBLISHING
2022
AUTHORS
WHO

Categories

For implementers
KEY ORGANIZATIONS

FOLLOW US

Disclaimer: This website is made possible by the support of the American People through the United States Agency for International Development (USAID). The Learning4impact partnership is supported by USAID/India Health Office, under Cooperative Agreement # 72038618CA00001 with Swasti. The information provided on this website is not official U.S. Government information and does not necessarily represent the views or positions of USAID, the United States Government, or Swasti.
Copyright 2022 Swasti Health Catalyst